Pregnant or nursing

Have received treatment with any B cell targeted therapy.

Have received treatment with a biological investigational agent in the past year.

Have received IV cyclophosphamide within 180 days of Day 0.

Have severe lupus kidney disease.

Have active central nervous system (CNS) lupus.

Have required management of acute or chronic infections within the past 60 days.

Have current drug or alcohol abuse or dependence.

Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus